Natixis Advisors LLC Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Natixis Advisors LLC grew its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 22,834 shares of the specialty pharmaceutical company’s stock after buying an additional 1,603 shares during the quarter. Natixis Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $2,544,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Versant Capital Management Inc lifted its stake in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth $29,000. EverSource Wealth Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at $33,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Up 1.3 %

NASDAQ:JAZZ opened at $126.67 on Monday. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a fifty day simple moving average of $113.65 and a 200-day simple moving average of $110.73. The company has a market capitalization of $7.66 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. TD Cowen lowered their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Needham & Company LLC reissued a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday. HC Wainwright restated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday. Finally, StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $175.33.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,110 shares of company stock worth $720,160. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.